Cargando…

Model-Informed Precision Dosing of Linezolid in Patients with Drug-Resistant Tuberculosis

Linezolid is an efficacious medication for the treatment of drug-resistant tuberculosis but has been associated with serious safety issues that can result in treatment interruption. The objectives of this study were thus to build a population pharmacokinetic model and to use the developed model to e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mockeliunas, Laurynas, Keutzer, Lina, Sturkenboom, Marieke G. G., Bolhuis, Mathieu S., Hulskotte, Lotte M. G., Akkerman, Onno W., Simonsson, Ulrika S. H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032906/ https://www.ncbi.nlm.nih.gov/pubmed/35456587 http://dx.doi.org/10.3390/pharmaceutics14040753

Ejemplares similares

Derivation and Clinical Utility of Safety Targets for Linezolid-Related Adverse Events in Drug-Resistant Tuberculosis Treatment
por: Keutzer, Lina, et al.
Publicado: (2023)

Individualized Dosing With High Inter-Occasion Variability Is Correctly Handled With Model-Informed Precision Dosing—Using Rifampicin as an Example
por: Keutzer, Lina, et al.
Publicado: (2020)

Mobile Health Apps for Improvement of Tuberculosis Treatment: Descriptive Review
por: Keutzer, Lina, et al.
Publicado: (2020)

Medical Device Apps: An Introduction to Regulatory Affairs for Developers
por: Keutzer, Lina, et al.
Publicado: (2020)

A modeling‐based proposal for safe and efficacious reintroduction of bedaquiline after dose interruption: A population pharmacokinetics study
por: Keutzer, Lina, et al.
Publicado: (2022)

Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug development
por: Mockeliunas, Laurynas, et al.
Publicado: (2023)

Malnutrition assessment methods in adult patients with tuberculosis: a systematic review
por: ter Beek, Lies, et al.
Publicado: (2021)

Seasonal influence on respiratory tract infection severity including COVID‐19 quantified through Markov Chain modeling
por: van Wijk, Rob C., et al.
Publicado: (2023)

Safety of Rifampicin at High Dose for Difficult-to-Treat Tuberculosis: Protocol for RIAlta Phase 2b/c Trial
por: Espinosa-Pereiro, Juan, et al.
Publicado: (2022)

Reproducibility in pharmacometrics applied in a phase III trial of BCG-vaccination for COVID-19
por: van Wijk, Rob C., et al.
Publicado: (2023)

Population pharmacokinetics and dose evaluations of linezolid in the treatment of multidrug-resistant tuberculosis
por: Zhang, Haoyue, et al.
Publicado: (2023)

Low-Dose Linezolid for Treatment of Patients With Multidrug-Resistant Tuberculosis
por: Mase, Anjeli, et al.
Publicado: (2022)

Linezolid Dose That Maximizes Sterilizing Effect While Minimizing Toxicity and Resistance Emergence for Tuberculosis
por: Srivastava, Shashikant, et al.
Publicado: (2017)

Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children With Disseminated Tuberculosis: Goldilocks
por: Srivastava, Shashikant, et al.
Publicado: (2016)

Linezolid for Infants and Toddlers With Disseminated Tuberculosis: First Steps
por: Deshpande, Devyani, et al.
Publicado: (2016)

Linezolid for drug‐resistant pulmonary tuberculosis
por: Singh, Bhagteshwar, et al.
Publicado: (2019)

Corrigendum to “Mass spectrometry for therapeutic drug monitoring of anti-tuberculosis drugs” [Clin. Mass Spectrom. 14(Part A) (2019) 34–45]
por: Kuhlin, Johanna, et al.
Publicado: (2022)

Low Rate of Acquired Linezolid Resistance in Multidrug-Resistant Tuberculosis Treated With Bedaquiline-Linezolid Combination
por: Du, Jian, et al.
Publicado: (2021)

Linezolid-resistant Mycobacterium tuberculosis: Will it impact the tuberculosis elimination programme?
por: Bharadwaj, Renu
Publicado: (2021)

Proposed Linezolid Dosing Strategies to Minimize Adverse Events for Treatment of Extensively Drug-Resistant Tuberculosis
por: Imperial, Marjorie Z, et al.
Publicado: (2021)

Forecasting Clinical Dose–Response From Preclinical Studies in Tuberculosis Research: Translational Predictions With Rifampicin
por: Wicha, Sebastian G., et al.
Publicado: (2018)

Machine Learning and Pharmacometrics for Prediction of Pharmacokinetic Data: Differences, Similarities and Challenges Illustrated with Rifampicin
por: Keutzer, Lina, et al.
Publicado: (2022)

Linezolid for Treating Tuberculosis: A Delicate Balancing Act
por: Maartens, Gary, et al.
Publicado: (2015)

A Model-Informed Method for the Purpose of Precision Dosing of Isoniazid in Pulmonary Tuberculosis
por: van Beek, Stijn W., et al.
Publicado: (2021)

Evaluation of IL-1 Blockade as an Adjunct to Linezolid Therapy for Tuberculosis in Mice and Macaques
por: Winchell, Caylin G., et al.
Publicado: (2020)

Linezolid in the Starter Combination for Multidrug-Resistant Tuberculosis: Time to Move on to Group Four?
por: Grard, Soazic, et al.
Publicado: (2015)

Concentration-Dependent Synergy and Antagonism of Linezolid and Moxifloxacin in the Treatment of Childhood Tuberculosis: The Dynamic Duo
por: Deshpande, Devyani, et al.
Publicado: (2016)

Phase III dose selection of marzeptacog alfa (activated) informed by population pharmacokinetic modeling: A novel hemostatic drug
por: Faraj, Alan, et al.
Publicado: (2022)

Preclinical Evaluations To Identify Optimal Linezolid Regimens for Tuberculosis Therapy
por: Brown, Ashley N., et al.
Publicado: (2015)

Bedaquiline and Linezolid for Extensively Drug-Resistant Tuberculosis in Pregnant Woman
por: Jaspard, Marie, et al.
Publicado: (2017)

Pharmacodynamic Correlates of Linezolid Activity and Toxicity in Murine Models of Tuberculosis
por: Bigelow, Kristina M, et al.
Publicado: (2020)

Model‐informed pediatric dose selection of marzeptacog alfa (activated): An exposure matching strategy
por: Faraj, Alan, et al.
Publicado: (2023)

Model-Informed Support of Dose Selection for Prophylactic Treatment with Dalcinonacog Alfa in Adult and Paediatric Hemophilia B Patients
por: Faraj, Alan, et al.
Publicado: (2023)

Linezolid pharmacokinetics in MDR-TB: a systematic review, meta-analysis and Monte Carlo simulation
por: Millard, James, et al.
Publicado: (2018)

Tolerability and pharmacokinetic evaluation of inhaled dry powder hydroxychloroquine in healthy volunteers
por: de Reus, Y. A., et al.
Publicado: (2022)

Correction to: A Model-Informed Method for the Purpose of Precision Dosing of Isoniazid in Pulmonary Tuberculosis
por: van Beek, Stijn W., et al.
Publicado: (2021)

Changes in chest CT findings of pulmonary tuberculosis after linezolid treatment
por: Kim, Sanghyeon, et al.
Publicado: (2013)

Graphene Oxide-Linezolid Combination as Potential New Anti-Tuberculosis Treatment
por: De Maio, Flavio, et al.
Publicado: (2020)

Linezolid-Associated Neuropathy in Patients with MDR/XDR Tuberculosis in Shenzhen, China
por: Zhang, Peize, et al.
Publicado: (2022)

Mechanism underlying linezolid-induced peripheral neuropathy in multidrug-resistant tuberculosis
por: Yuan, Yuan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tpb6e8ivl0pkqvdo6t06anrk9h